메뉴 건너뛰기




Volumn 6, Issue 34, 2015, Pages 36456-36471

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo

Author keywords

ABT263; Apoptotic resistance; Glioblastoma; Multi targeting; TIC10 ONC201

Indexed keywords

ANTINEOPLASTIC AGENT; CHAPERONE; DEUBIQUITINASE; NAVITOCLAX; PROTEIN BAG3; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN USP9X; TRAIL INDUCING COMPOUND 10; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; BCL2L1 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; MCL1 PROTEIN, HUMAN; PROTEIN BCL X; SULFONAMIDE; TIC10 COMPOUND;

EID: 84946866494     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5505     Document Type: Article
Times cited : (58)

References (54)
  • 4
    • 84874051647 scopus 로고    scopus 로고
    • Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects
    • Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013; 5:171ra117.
    • (2013) Sci Transl Med , vol.5
    • Allen, J.E.1    Krigsfeld, G.2    Mayes, P.A.3    Patel, L.4    Dicker, D.T.5    Patel, A.S.6
  • 5
    • 84929149021 scopus 로고    scopus 로고
    • Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
    • Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, et al. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015; 14:99.
    • (2015) Mol Cancer , vol.14 , pp. 99
    • Allen, J.E.1    Krigsfeld, G.2    Patel, L.3    Mayes, P.A.4    Dicker, D.T.5    Wu, G.S.6
  • 6
    • 84929220564 scopus 로고    scopus 로고
    • Genetic and pharmacological screens converge in identifying FLIP, BCL2, and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anticancer agent ONC201/TIC10
    • Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, et al. Genetic and pharmacological screens converge in identifying FLIP, BCL2, and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anticancer agent ONC201/TIC10. Cancer Res. 2015; 75:1668-1674.
    • (2015) Cancer Res , vol.75 , pp. 1668-1674
    • Allen, J.E.1    Prabhu, V.V.2    Talekar, M.3    van den Heuvel, A.P.4    Lim, B.5    Dicker, D.T.6
  • 7
    • 84929220565 scopus 로고    scopus 로고
    • Smallmolecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/TRAILdependent manner
    • Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Smallmolecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/TRAILdependent manner. Cancer Res. 2015; 75:1423-1432.
    • (2015) Cancer Res , vol.75 , pp. 1423-1432
    • Prabhu, V.V.1    Allen, J.E.2    Dicker, D.T.3    El-Deiry, W.S.4
  • 8
    • 84946828848 scopus 로고    scopus 로고
    • TIC10/ONC201: a bend in the road to clinical development
    • Greer YE, Lipkowitz S. TIC10/ONC201: a bend in the road to clinical development. Oncoscience. 2015; 2:75-76.
    • (2015) Oncoscience , vol.2 , pp. 75-76
    • Greer, Y.E.1    Lipkowitz, S.2
  • 9
    • 84865736998 scopus 로고    scopus 로고
    • Targeting the B-cell lymphoma/leukemia 2 family in cancer
    • Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 2012; 30:3127-3135.
    • (2012) J Clin Oncol , vol.30 , pp. 3127-3135
    • Davids, M.S.1    Letai, A.2
  • 10
    • 54949132875 scopus 로고    scopus 로고
    • Bcl-2 family proteins and cancer
    • Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008; 27:6398-6406.
    • (2008) Oncogene , vol.27 , pp. 6398-6406
    • Yip, K.W.1    Reed, J.C.2
  • 11
    • 79952291173 scopus 로고    scopus 로고
    • Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors
    • Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011; 29:909-916.
    • (2011) J Clin Oncol , vol.29 , pp. 909-916
    • Gandhi, L.1    Camidge, D.R.2    Ribeiro de Oliveira, M.3    Bonomi, P.4    Gandara, D.5    Khaira, D.6
  • 12
    • 84947566364 scopus 로고    scopus 로고
    • A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
    • Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil I, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 1-30.
    • (2015) Leuk Lymphoma , pp. 1-30
    • Kipps, T.J.1    Eradat, H.2    Grosicki, S.3    Catalano, J.4    Cosolo, W.5    Dyagil, I.6
  • 13
    • 84863116430 scopus 로고    scopus 로고
    • Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease
    • Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2011; 30:488-496.
    • (2011) J Clin Oncol , vol.30 , pp. 488-496
    • Roberts, A.W.1    Seymour, J.F.2    Brown, J.R.3    Wierda, W.G.4    Kipps, T.J.5    Khaw, S.L.6
  • 14
    • 78649630259 scopus 로고    scopus 로고
    • Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
    • Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010; 11:1149-1159.
    • (2010) Lancet Oncol , vol.11 , pp. 1149-1159
    • Wilson, W.H.1    O'Connor, O.A.2    Czuczman, M.S.3    LaCasce, A.S.4    Gerecitano, J.F.5    Leonard, J.P.6
  • 15
    • 0032929520 scopus 로고    scopus 로고
    • Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
    • Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5:157-163.
    • (1999) Nat Med , vol.5 , pp. 157-163
    • Walczak, H.1    Miller, R.E.2    Ariail, K.3    Gliniak, B.4    Griffith, T.S.5    Kubin, M.6
  • 16
    • 0036341291 scopus 로고    scopus 로고
    • Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
    • Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002; 8:808-815.
    • (2002) Nat Med , vol.8 , pp. 808-815
    • Fulda, S.1    Wick, W.2    Weller, M.3    Debatin, K.M.4
  • 17
    • 0033584823 scopus 로고    scopus 로고
    • Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity
    • Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J, et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun. 1999; 265:479-483.
    • (1999) Biochem Biophys Res Commun , vol.265 , pp. 479-483
    • Roth, W.1    Isenmann, S.2    Naumann, U.3    Kugler, S.4    Bahr, M.5    Dichgans, J.6
  • 18
    • 79953317434 scopus 로고    scopus 로고
    • Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells
    • Siegelin MD, Dohi T, Raskett CM, Orlowski GM, Powers CM, Gilbert CA, et al. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest. 2011; 121:1349-1360.
    • (2011) J Clin Invest , vol.121 , pp. 1349-1360
    • Siegelin, M.D.1    Dohi, T.2    Raskett, C.M.3    Orlowski, G.M.4    Powers, C.M.5    Gilbert, C.A.6
  • 19
    • 84907971362 scopus 로고    scopus 로고
    • CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
    • Kast RE, Karpel-Massler G, Halatsch ME. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget. 2014; 5:8052-8082.
    • (2014) Oncotarget , vol.5 , pp. 8052-8082
    • Kast, R.E.1    Karpel-Massler, G.2    Halatsch, M.E.3
  • 20
    • 84903273093 scopus 로고    scopus 로고
    • Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL
    • Jacob NT, Lockner JW, Kravchenko VV, Janda KD. Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL. Angew Chem Int Ed Engl. 2014; 53:6628-6631.
    • (2014) Angew Chem Int Ed Engl , vol.53 , pp. 6628-6631
    • Jacob, N.T.1    Lockner, J.W.2    Kravchenko, V.V.3    Janda, K.D.4
  • 21
    • 56149097601 scopus 로고    scopus 로고
    • Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins
    • Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC, et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene. 2008; 27:6646-6656.
    • (2008) Oncogene , vol.27 , pp. 6646-6656
    • Tagscherer, K.E.1    Fassl, A.2    Campos, B.3    Farhadi, M.4    Kraemer, A.5    Bock, B.C.6
  • 22
    • 84859939822 scopus 로고    scopus 로고
    • Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1
    • Cruickshanks N, Hamed HA, Bareford MD, Poklepovic A, Fisher PB, Grant S, et al. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Mol Pharmacol. 2012; 81:748-758.
    • (2012) Mol Pharmacol , vol.81 , pp. 748-758
    • Cruickshanks, N.1    Hamed, H.A.2    Bareford, M.D.3    Poklepovic, A.4    Fisher, P.B.5    Grant, S.6
  • 23
    • 73849083434 scopus 로고    scopus 로고
    • Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
    • Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010; 463:103-107.
    • (2010) Nature , vol.463 , pp. 103-107
    • Schwickart, M.1    Huang, X.2    Lill, J.R.3    Liu, J.4    Ferrando, R.5    French, D.M.6
  • 24
    • 84874817068 scopus 로고    scopus 로고
    • The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737
    • Boiani M, Daniel C, Liu X, Hogarty MD, Marnett LJ. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737. J Biol Chem. 2013; 288:6980-6990.
    • (2013) J Biol Chem , vol.288 , pp. 6980-6990
    • Boiani, M.1    Daniel, C.2    Liu, X.3    Hogarty, M.D.4    Marnett, L.J.5
  • 25
    • 3142683869 scopus 로고    scopus 로고
    • MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol
    • Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004; 23:5301-5315.
    • (2004) Oncogene , vol.23 , pp. 5301-5315
    • Domina, A.M.1    Vrana, J.A.2    Gregory, M.A.3    Hann, S.R.4    Craig, R.W.5
  • 26
    • 84947492264 scopus 로고    scopus 로고
    • Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer
    • advance online publication 5 June 2015
    • Goodwin CM, Rossanese OW, Olejniczak ET, Fesik SW. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death Differ. 2015; advance online publication 5 June 2015.
    • (2015) Cell Death Differ
    • Goodwin, C.M.1    Rossanese, O.W.2    Olejniczak, E.T.3    Fesik, S.W.4
  • 27
    • 84874854237 scopus 로고    scopus 로고
    • YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context
    • Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Mol Cancer Ther. 2013; 12:326-338.
    • (2013) Mol Cancer Ther , vol.12 , pp. 326-338
    • Jane, E.P.1    Premkumar, D.R.2    DiDomenico, J.D.3    Hu, B.4    Cheng, S.Y.5    Pollack, I.F.6
  • 28
    • 84931075379 scopus 로고    scopus 로고
    • Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
    • Karpel-Massler G, Shu C, Chau L, Banu M, Halatsch ME, Westhoff MA, et al. Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo. Oncotarget. 2015; 6:14507-14521.
    • (2015) Oncotarget , vol.6 , pp. 14507-14521
    • Karpel-Massler, G.1    Shu, C.2    Chau, L.3    Banu, M.4    Halatsch, M.E.5    Westhoff, M.A.6
  • 29
    • 33750628289 scopus 로고    scopus 로고
    • Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
    • Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006; 10:375-388.
    • (2006) Cancer Cell , vol.10 , pp. 375-388
    • Konopleva, M.1    Contractor, R.2    Tsao, T.3    Samudio, I.4    Ruvolo, P.P.5    Kitada, S.6
  • 30
    • 84937778664 scopus 로고    scopus 로고
    • Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia
    • Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, et al. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 2015; 126:363-372.
    • (2015) Blood , vol.126 , pp. 363-372
    • Pan, R.1    Ruvolo, V.R.2    Wei, J.3    Konopleva, M.4    Reed, J.C.5    Pellecchia, M.6
  • 31
    • 84904267338 scopus 로고    scopus 로고
    • PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD
    • Pareja F, Macleod D, Shu C, Crary JF, Canoll PD, Ross AH, et al. PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res. 2014; 12:987-1001.
    • (2014) Mol Cancer Res , vol.12 , pp. 987-1001
    • Pareja, F.1    Macleod, D.2    Shu, C.3    Crary, J.F.4    Canoll, P.D.5    Ross, A.H.6
  • 32
    • 84872601365 scopus 로고    scopus 로고
    • Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage
    • Premkumar DR, Jane EP, Agostino NR, DiDomenico JD, Pollack IF. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol Carcinog. 2013; 52:118-133.
    • (2013) Mol Carcinog , vol.52 , pp. 118-133
    • Premkumar, D.R.1    Jane, E.P.2    Agostino, N.R.3    DiDomenico, J.D.4    Pollack, I.F.5
  • 34
    • 33749016520 scopus 로고    scopus 로고
    • A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo
    • Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res. 2006; 66:8731-8739.
    • (2006) Cancer Res , vol.66 , pp. 8731-8739
    • Shoemaker, A.R.1    Oleksijew, A.2    Bauch, J.3    Belli, B.A.4    Borre, T.5    Bruncko, M.6
  • 35
    • 84891892155 scopus 로고    scopus 로고
    • mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1
    • Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov. 2014; 4:42-52.
    • (2014) Cancer Discov , vol.4 , pp. 42-52
    • Faber, A.C.1    Coffee, E.M.2    Costa, C.3    Dastur, A.4    Ebi, H.5    Hata, A.N.6
  • 36
    • 79959376413 scopus 로고    scopus 로고
    • BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy
    • Festa M, Del Valle L, Khalili K, Franco R, Scognamiglio G, Graziano V, et al. BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol. 2011; 178:2504-2512.
    • (2011) Am J Pathol , vol.178 , pp. 2504-2512
    • Festa, M.1    Del Valle, L.2    Khalili, K.3    Franco, R.4    Scognamiglio, G.5    Graziano, V.6
  • 37
    • 84867806661 scopus 로고    scopus 로고
    • Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1
    • Trivigno D, Essmann F, Huber SM, Rudner J. Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. Neoplasia. 2012; 14:893-904.
    • (2012) Neoplasia , vol.14 , pp. 893-904
    • Trivigno, D.1    Essmann, F.2    Huber, S.M.3    Rudner, J.4
  • 38
    • 84905492796 scopus 로고    scopus 로고
    • Usp9xand Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells
    • Yan J, Zhong N, Liu G, Chen K, Liu X, Su L, et al. Usp9xand Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells. Cell Death Dis. 2014; 5:e1316.
    • (2014) Cell Death Dis , vol.5
    • Yan, J.1    Zhong, N.2    Liu, G.3    Chen, K.4    Liu, X.5    Su, L.6
  • 39
    • 79960146856 scopus 로고    scopus 로고
    • Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1
    • Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H, Dong XW, et al. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther. 2011; 10:1264-1275.
    • (2011) Mol Cancer Ther , vol.10 , pp. 1264-1275
    • Zhang, C.1    Cai, T.Y.2    Zhu, H.3    Yang, L.Q.4    Jiang, H.5    Dong, X.W.6
  • 41
    • 84872387485 scopus 로고    scopus 로고
    • Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
    • Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 2013; 23:121-128.
    • (2013) Cancer Cell , vol.23 , pp. 121-128
    • Corcoran, R.B.1    Cheng, K.A.2    Hata, A.N.3    Faber, A.C.4    Ebi, H.5    Coffee, E.M.6
  • 42
    • 38749084498 scopus 로고    scopus 로고
    • A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation
    • Lee EF, Czabotar PE, van Delft MF, Michalak EM, Boyle MJ, Willis SN, et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol. 2008; 180:341-355.
    • (2008) J Cell Biol , vol.180 , pp. 341-355
    • Lee, E.F.1    Czabotar, P.E.2    van Delft, M.F.3    Michalak, E.M.4    Boyle, M.J.5    Willis, S.N.6
  • 43
    • 84942103252 scopus 로고    scopus 로고
    • MCL-1 is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor
    • Xiao Y, Nimmer P, Sheppard GS, Bruncko M, Hessler P, Lu X, et al. MCL-1 is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor. Mol Cancer Ther. 2015; 14:1837-47.
    • (2015) Mol Cancer Ther , vol.14 , pp. 1837-1847
    • Xiao, Y.1    Nimmer, P.2    Sheppard, G.S.3    Bruncko, M.4    Hessler, P.5    Lu, X.6
  • 44
    • 66449130084 scopus 로고    scopus 로고
    • Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737
    • Hauck P, Chao BH, Litz J, Krystal GW. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther. 2009; 8:883-892.
    • (2009) Mol Cancer Ther , vol.8 , pp. 883-892
    • Hauck, P.1    Chao, B.H.2    Litz, J.3    Krystal, G.W.4
  • 45
    • 84862586485 scopus 로고    scopus 로고
    • Mcl-1 phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells
    • Mazumder S, Choudhary GS, Al-Harbi S, Almasan A. Mcl-1 phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res. 2012; 72:3069-3079.
    • (2012) Cancer Res , vol.72 , pp. 3069-3079
    • Mazumder, S.1    Choudhary, G.S.2    Al-Harbi, S.3    Almasan, A.4
  • 46
    • 84922604221 scopus 로고    scopus 로고
    • Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells
    • Mukherjee N, Reuland SN, Lu Y, Luo Y, Lambert K, Fujita M, et al. Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. J Invest Dermatol. 2015; 135:842-850.
    • (2015) J Invest Dermatol , vol.135 , pp. 842-850
    • Mukherjee, N.1    Reuland, S.N.2    Lu, Y.3    Luo, Y.4    Lambert, K.5    Fujita, M.6
  • 47
    • 84865733257 scopus 로고    scopus 로고
    • Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
    • Rooswinkel RW, van de Kooij B, Verheij M, Borst J. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis. 2012; 3:e366.
    • (2012) Cell Death Dis , vol.3
    • Rooswinkel, R.W.1    van de Kooij, B.2    Verheij, M.3    Borst, J.4
  • 48
    • 65649086790 scopus 로고    scopus 로고
    • Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation
    • Capper D, Gaiser T, Hartmann C, Habel A, Mueller W, Herold-Mende C, et al. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol. 2009; 117:445-456.
    • (2009) Acta Neuropathol , vol.117 , pp. 445-456
    • Capper, D.1    Gaiser, T.2    Hartmann, C.3    Habel, A.4    Mueller, W.5    Herold-Mende, C.6
  • 49
    • 84870478666 scopus 로고    scopus 로고
    • ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells
    • Cristofanon S, Fulda S. ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis. 2012; 3:e432.
    • (2012) Cell Death Dis , vol.3
    • Cristofanon, S.1    Fulda, S.2
  • 50
    • 0032977124 scopus 로고    scopus 로고
    • Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines
    • Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999; 9:469-479.
    • (1999) Brain Pathol , vol.9 , pp. 469-479
    • Ishii, N.1    Maier, D.2    Merlo, A.3    Tada, M.4    Sawamura, Y.5    Diserens, A.C.6
  • 51
    • 84884519445 scopus 로고    scopus 로고
    • Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells
    • Karpel-Massler G, Westhoff MA, Zhou S, Nonnenmacher L, Dwucet A, Kast RE, et al. Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. Mol Cancer Ther. 2013; 12:1783-1795.
    • (2013) Mol Cancer Ther , vol.12 , pp. 1783-1795
    • Karpel-Massler, G.1    Westhoff, M.A.2    Zhou, S.3    Nonnenmacher, L.4    Dwucet, A.5    Kast, R.E.6
  • 52
    • 84925511559 scopus 로고    scopus 로고
    • Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect
    • Karpel-Massler G, Kast RE, Westhoff MA, Dwucet A, Welscher N, Nonnenmacher L, et al. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect. J Neurooncol. 2015; 122:21-33.
    • (2015) J Neurooncol , vol.122 , pp. 21-33
    • Karpel-Massler, G.1    Kast, R.E.2    Westhoff, M.A.3    Dwucet, A.4    Welscher, N.5    Nonnenmacher, L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.